MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Gilead Sciences Inc.

Отворен

СекторЗдравеопазване

103.51 -3.51

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

100.88

Максимум

106.69

Ключови измерители

By Trading Economics

Приходи

530M

1.8B

Продажби

29M

7.6B

P/E

Средно за сектора

274.553

57.333

EPS

1.9

Дивидентна доходност

3.02

Марж на печалбата

23.557

Служители

17,600

EBITDA

-655M

3.1B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+9.79% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.02%

2.63%

Следваща дата на дивидент

26.06.2025 г.

Следваща дата на екс-дивидент

13.06.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

8.7B

130B

Предишно отваряне

107.02

Предишно затваряне

103.51

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Gilead Sciences Inc. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2025 г., 20:17 ч. UTC

Печалби

Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance

11.02.2025 г., 21:17 ч. UTC

Печалби

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

24.04.2025 г., 20:08 ч. UTC

Печалби

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences: As of March 31, 2025, $7.9 Billion of Cash and Cash Equivalents Compared to $10.0 Billion as of Dec. 31, 2024 >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences 1Q Rev $6.67B >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences: 1Q Product Gross Margin Was 76.7% Compared to 76.6% in Same Period in 2024 >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences: During 1Q Generated $1.8 Billion in Operating Cash Flow >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences: 1Q Lower Veklury (Remdesivir) and Oncology Sales Offset by Higher HIV and Liver Disease Sales >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences Sees 2025 EPS $5.65-EPS $6.05 >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences 1Q EPS $1.04 >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences 1Q EPS $1.04 >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences Sees FY EPS $5.65-EPS $6.05 >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences 1Q Total Liver Disease Sales $758M >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences 1Q Net $1.32B >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences 1Q Adj EPS $1.81 >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences Sees FY Adj EPS $7.70-Adj EPS $8.10 >GILD

24.04.2025 г., 20:02 ч. UTC

Печалби

Gilead Sciences 1Q Rev $6.7B >GILD

11.04.2025 г., 09:30 ч. UTC

Топ новини

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

19.03.2025 г., 14:50 ч. UTC

Топ новини

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11.02.2025 г., 22:13 ч. UTC

Пазарно говорене
Печалби

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

11.02.2025 г., 21:06 ч. UTC

Печалби

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

11.02.2025 г., 21:02 ч. UTC

Печалби

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

11.02.2025 г., 21:02 ч. UTC

Печалби

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

11.02.2025 г., 21:02 ч. UTC

Печалби

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

11.02.2025 г., 21:02 ч. UTC

Печалби

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

11.02.2025 г., 21:02 ч. UTC

Печалби

Gilead Sciences Raises Dividend 2.6%>GILD

11.02.2025 г., 21:02 ч. UTC

Печалби

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

Сравнение с други в отрасъла

Ценова промяна

Gilead Sciences Inc. Прогноза

Ценова цел

By TipRanks

9.79% нагоре

12-месечна прогноза

Среден 116.79 USD  9.79%

Висок 140 USD

Нисък 89 USD

Според 24 анализатори от Wall Street, предложили 12-месечна ценова цел за Gilead Sciences Inc. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

24 ratings

18

Купи

6

Задържане

0

Продай

Техническа оценка

By Trading Central

105 / 106.5Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Very Strong Bearish Evidence

Дългосрочен план

Weak Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.